Capital Focus Domain Associates manages 2.4 billion in capital and concentrates on life science investments across pharmaceuticals, diagnostics, and medical devices, indicating potential upsell opportunities with portfolio companies seeking growth-stage funding, strategic partnerships, or exits.

Experience & Network With a long track record since 1985, eight funds raised, and involvement in over 250 portfolio companies, Domain offers a deep network and credibility that can be leveraged for co-investments, clinical partnerships, or market access collaborations for portfolio firms.

Global Collaboration Domain has pursued international collaborations, including Russia and China through Rusnano and Beijing Elite, suggesting openness to global partnerships, licensing deals, and cross-border commercialization opportunities for relevant life science ventures.

Technology Stack The firm’s tech usage lists cloud and web technologies (AWS, PHP, RequireJS, Modernizr) alongside security (Mimecast) and analytics-friendly web presence, signaling potential needs for digital enablement services, data platforms, and regulatory-compliant IT optimizations for portfolio companies.

Recent Investments Past investments in Seraphina Therapeutics and Adynxx demonstrate active late-stage biotech funding and therapeutic platforms, presenting opportunities for vendors offering clinical development services, regulatory consulting, or manufacturing scale-up support to similar life science startups.